Shopping Cart
- Remove All
- Your shopping cart is currently empty
Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor (IC50: 18 nM) that also inhibits COX-1 activity (IC50: 115 nM) and exhibits anti-inflammatory effects.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 28 € | In Stock | |
50 mg | Inquiry | In Stock | |
1 mL x 10 mM (in DMSO) | 40 € | In Stock |
Description | Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor (IC50: 18 nM) that also inhibits COX-1 activity (IC50: 115 nM) and exhibits anti-inflammatory effects. |
Targets&IC50 | COX-1:115 nM, COX-2(human):18 nM, COX-2:115 nM |
In vitro | In U937 cells, Imrecoxib (0.1-10 μM; 24 hours) reduces COX-2 mRNA level induced by PMA+LPS in a dose-dependent manner. |
In vivo | Imrecoxib (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling. It also inhibits heat-inactivated BCG induced-inflammtory polyarthritis. Imrecoxib (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) suppresses carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours. |
Alias | BAP-909 |
Molecular Weight | 369.48 |
Formula | C21H23NO3S |
Cas No. | 395683-14-4 |
Smiles | CCCN1CC(=C(C1=O)c1ccc(C)cc1)c1ccc(cc1)S(C)(=O)=O |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90 mg/mL (243.59 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.